Morgan Stanley Raises Tenet Healthcare (THC) PT to $210, Keeps Overweight Rating

Tenet Healthcare Corporation (NYSE:THC) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, Morgan Stanley raised its price target on Tenet Healthcare to $210 from $175, while maintaining an Overweight rating on the shares. Analyst Craig Hettenbach highlighted Tenet Healthcare as Morgan Stanley’s preferred stock within the hospital sector.

Tenet Healthcare’s net operating revenues in Q1 2o25 were $5.2 billion. The company’s consolidated Adjusted EBITDA increased by 14% over Q1 2024 to $1.163 billion, with an Adjusted EBITDA Margin of 22.3%, which shows a 3.2% improvement over the prior year. USPI/United Surgical Partners International Adjusted EBITDA alone grew 16% year-over-year in Q1 to $456 million, while the same-facility revenues increased by 6.8%.

A room full of medical personnel collaborating on a treatment plan for a patient.

Tenet Healthcare plans to deploy $250 million annually for USPI acquisitions, with a focus on diversifying service lines like orthopedics. Despite the strong performance, Tenet Healthcare is not updating its full-year 2025 guidance due to the early stage of the year and potential uncertainties.

Tenet Healthcare Corporation (NYSE:THC) is a diversified healthcare services company in the US. The company operates through 2 segments: Hospital Operations & Services, and Ambulatory Care.

While we acknowledge the potential of THC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.